Community Bank N.A. Purchases 1,835 Shares of Johnson & Johnson (NYSE:JNJ)

Community Bank N.A. increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,656 shares of the company's stock after buying an additional 1,835 shares during the quarter. Johnson & Johnson makes up 1.1% of Community Bank N.A.'s holdings, making the stock its 22nd biggest position. Community Bank N.A.'s holdings in Johnson & Johnson were worth $7,903,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Kiley Juergens Wealth Management LLC increased its position in shares of Johnson & Johnson by 2.5% in the first quarter. Kiley Juergens Wealth Management LLC now owns 17,909 shares of the company's stock worth $2,970,000 after purchasing an additional 435 shares during the period. State of Alaska Department of Revenue grew its position in Johnson & Johnson by 14.5% in the first quarter. State of Alaska Department of Revenue now owns 352,378 shares of the company's stock valued at $58,437,000 after acquiring an additional 44,600 shares during the last quarter. CWA Asset Management Group LLC grew its position in Johnson & Johnson by 2.6% in the first quarter. CWA Asset Management Group LLC now owns 123,552 shares of the company's stock valued at $20,490,000 after acquiring an additional 3,074 shares during the last quarter. Analyst IMS Investment Management Services Ltd. grew its position in Johnson & Johnson by 43.0% in the first quarter. Analyst IMS Investment Management Services Ltd. now owns 10,380 shares of the company's stock valued at $1,722,000 after acquiring an additional 3,121 shares during the last quarter. Finally, LifeWealth Investments LLC grew its position in Johnson & Johnson by 11.6% in the first quarter. LifeWealth Investments LLC now owns 1,741 shares of the company's stock valued at $289,000 after acquiring an additional 181 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on JNJ shares. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Barclays dropped their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Price Performance

Shares of JNJ traded down $0.92 during trading hours on Friday, reaching $149.81. 22,591,152 shares of the company's stock traded hands, compared to its average volume of 8,022,556. The stock has a market cap of $360.44 billion, a PE ratio of 16.66, a price-to-earnings-growth ratio of 2.28 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The firm's 50 day simple moving average is $154.07 and its 200-day simple moving average is $153.63. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.47%. Johnson & Johnson's payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.